LABT (Lakewood-Amedex Biotherapeutics) Interest Expense: $-0.11 Mil (TTM As of Mar. 2026)


LABT Lakewood-Amedex Biotherapeutics Inc LABT
8 GF Score
Price $3.55
View Full Analysis

What is Lakewood-Amedex Biotherapeutics Interest Expense?

Lakewood-Amedex Biotherapeutics LABT +2.33% 8 Interest Expense is $-0.11 Mil as of Mar. 2026. GuruFocus rates LABT with a GF Score™ of 8/100.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lakewood-Amedex Biotherapeutics's interest expense for the three months ended in Mar. 2026 was $ -0.04 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.11 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lakewood-Amedex Biotherapeutics's Operating Income for the three months ended in Mar. 2026 was $ -0.89 Mil. Lakewood-Amedex Biotherapeutics's Interest Expense for the three months ended in Mar. 2026 was $ -0.04 Mil. Lakewood-Amedex Biotherapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lakewood-Amedex Biotherapeutics  (NAS:LABT) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lakewood-Amedex Biotherapeutics's Interest Expense for the three months ended in Mar. 2026 was $-0.04 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-0.89 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0.01 Mil.

Lakewood-Amedex Biotherapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Lakewood-Amedex Biotherapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Lakewood-Amedex Biotherapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Lakewood-Amedex Biotherapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakewood-Amedex Biotherapeutics Interest Expense Chart

Lakewood-Amedex Biotherapeutics Annual Data
Trend Dec23 Dec24 Dec25
Interest Expense
-0.01 -0.01 -0.10

Lakewood-Amedex Biotherapeutics Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial 0.00 -0.00 -0.04 -0.04 -0.04
LABT
8GF Score
Lakewood-Amedex Biotherapeutics Inc LABT
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakewood-Amedex Biotherapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.11 Mil mean?
Lakewood-Amedex Biotherapeutics (LABT) has a Interest Expense of $-0.11 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Lakewood-Amedex Biotherapeutics and its competitors.
Is Lakewood-Amedex Biotherapeutics' Interest Expense too high?
Lakewood-Amedex Biotherapeutics' current Interest Expense is $-0.11 Mil. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Interest Expense compare to CURX and PBM?
Lakewood-Amedex Biotherapeutics' Interest Expense of $-0.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. Lakewood-Amedex Biotherapeutics's current Interest Expense is $-0.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Interest Expense of $-0.11 Mil. The current Interest Expense is $-0.11 Mil. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Interest Expense is $-0.11 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lakewood-Amedex Biotherapeutics Business Description

Address 8031 Cooper Creek Blvd, Unit 103, University Park, FL, USA, 34201
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score

Get the complete analysis for LABT

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price